About

Ms. Prange was most recently Executive Vice President and Chief Executive Officer for the Global Animal Health, Medical and Dental Surgical Group at Henry Schein, Inc. and a member of its Executive Committee from 2016 to 2018. In this role, she led a business that generated over $6 billion of revenue across three different business units, growing the business to above-market levels in all business segments. Prior to her role at Henry Schein, she was Senior Vice President of Boston Scientific and President of its Urology and Pelvic Health business and served as General Manager of the Micrus Endovascular and Codman Neurovascular business at Johnson & Johnson Company.

Ms. Prange currently serves on the board of AtriCure, Inc. (NASDAQ: ATRC) and WS Audiology A/S. She has also served as Industrial Advisor to EQT Group, a global investment organization, since March 2020. She earned her Bachelor of Science in Business Administration with honors from the University of Florida and has completed executive education coursework at UCLA Anderson School of Business and Smith College.

Ms. Prange brings to the Board her public company governance experience and leadership experience in the medical industry, as well as extensive global business, strategy and innovation, payer and medical reimbursement, risk management, ESG and regulatory and compliance experience.

Roles

Embecta Corp.
Director · Current role
2022–present
Henry Schein, Inc.
Executive Vice President and Chief Executive Officer, Global Animal Health, Medical and Dental Surgical Group · Member of its Executive Committee; led a business generating over $6 billion of revenue across three business units.
2016 – 2018
Boston Scientific
Senior Vice President and President, Urology and Pelvic Health
Johnson & Johnson Company
General Manager, Micrus Endovascular and Codman Neurovascular business

External Roles

AtriCure, Inc. (NASDAQ: ATRC)
Director
WS Audiology A/S
Director
EQT Group
Industrial Advisor
Since March 2020
Cantel Medical Corporation
Director
ViewRay, Inc.
Director
Nevro Corp.
Director
Nuvo Group, LLC
Strategic Advisor
Since September 2019

Director Compensation

FY 2025
Fees earned or paid in cash
$96,000
Stock awards
$230,004
All other compensation
$2,000
Total
$328,004

Also at Embecta Corp.

Related

See how VectorShift works for your firm

Request Demo